Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 24Terminated 6Recruiting 4Active not recruiting 3Unknown 2Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 15Gastrointestinal 7Tumor-Agnostic 4Gynecologic 2Thoracic 1Breast 1

Conditions

Uterine Cervical Neoplasms 132Ovarian Neoplasms 109Endometrial Neoplasms 80Uterine Cervical Dysplasia 19Papillomavirus Infections 17Breast Neoplasms 16Fallopian Tube Neoplasms 15Carcinoma, Ovarian Epithelial 15Colorectal Neoplasms 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Vulvar Neoplasms 10Neoplasm Metastasis 10Recurrence 9Prostatic Neoplasms 9Endometrial Hyperplasia 9Cervical Cancer Screening 9Acquired Immunodeficiency Syndrome 8Uterine Neoplasms 7Stomach Neoplasms 7Squamous Intraepithelial Lesions 6Locally Advanced Cervical Cancer 6Anus Neoplasms 6Vaginal Neoplasms 5Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pelvic Neoplasms 5Pancreatic Neoplasms 5Melanoma 5

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Adenocarcinoma × Gynecologic × Clear all
NCT06834204 2026-03-23

ACCESS-PC

Rutgers, The State University of New Jersey

Phase NA Not yet recruiting
266 enrolled
GenitourinaryGynecologic

Adenocarcinoma, Urinary Bladder Neoplasms, Diabetes Mellitus, Hypercholesterolemia, Hyperlipidemias, Hypertension, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Erasmus Medical Center

Phase 2 Not yet recruiting
87 enrolled
Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡